Yükleniyor... / Loading...
This study looks at an intensive adjuvant (supportive) treatment approach after surgery in patients with triple-negative breast cancer (TNBC) who carry a BRCA1/2 mutation. It is enrolling patients with no distant metastasis after surgery who have completed postoperative chemotherapy and/or radiotherapy. It is being run as a study with no assigned phase and is enrolling by invitation.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * ECOG score 0-1 * TNBC * BRCA1/2 mutation * No distant metastases assessed by imaging after surgical treatment * Breast cancer that is non-pCR after neoadjuvant therapy, or postoperative pathology suggestive of ≥pT2, or ≥pN1 * Have completed postoperative adjuvant chemotherapy and/or radiotherapy * No major organ dysfunction Exclusion Criteria: * Patients who are unable to take oral medication, or who refuse this medication regimen * Already enrolled in another study, or less than or equal to 4 weeks from discontinuation of another medication * Presence of severe dysfunction of vital organs * Patients with other malignancies (with the exception of cured non-melanoma skin cancers, carcinoma in situ of the cervix and other tumours that have been cured for at least 5 years) * Acute infectious disease or active chronic infectious disease * History of uncontrolled epilepsy, central nervous system disease or mental disorder